TNFSF11 and osteoporosis: Denosumab, a human IgG2 antibody, is the first mAb targeted RANKL, approved for giant cell tumor of bone, postmenopausal women with osteoporosis at high risk for fracture, and multiple myeloma and bone metastasis from solid tumors in China.